Retrospective and prospective evaluation of the Amplicor HPV test for detection of 13 high-risk human papillomavirus genotypes on 862 clinical samples

Acta Dermatovenerologica Alpina, Pannonica et Adriatica

Volumn 14, Issue 4, 2005, Pages 147-152

  Poljak, Mario ^a   Fujs, Kristina ^a   Seme, Katja ^a   Kocjan, Boštjan J ^a   Vrtačnik Bokal, Eda ^b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Amplicor; HPV; Human papillomavirus; Hybride capture; PCR

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONSENSUS SEQUENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC KIT; EMERGENCY HEALTH SERVICE; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PERFORMANCE; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCREENING TEST; STANDARD; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS GENE; VIRUS TYPING; WART VIRUS;

DNA PROBES, HPV; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL DISEASES; VAGINAL SMEARS;

EID: 29744434314     PISSN: 13184458     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
2. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol 2005; 32 Suppl 1, S34-42.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, and International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348, 518-27.
4. Smith RA, Cokkinides V, Eyre HJ, American Cancer Society. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003; 53: 27-43.
5. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ, and ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287: 2120-9.
6. Davies P, Kornegay J, Iftner T. Current methods of testing for human papillomavirus. Best Pract Res Clin Obstet Gynaecol 2001; 15: 677-700.
7. van Doorn LJ, Kleter B, Quint WG. Molecular detection and genotyping of human papillomavirus. Expert Rev Mol Diagn 2001; 1: 394-402.
8. Poljak M, Brenčič A, Seme K, Vince A, Marin IJ. Comparative evaluation of first- and second-generation digene hybrid capture assays for detection of human papillomaviruses associated with high or intermediate risk for cervical cancer. J Clin Microbiol 1999; 37: 796-7.
9. Castle PE, Wheeler CM, Solomon D, Schiffman M, Peyton CL, ALTS Group. Interlaboratory reliability of Hybrid Capture 2. Am J Clin Pathol 2004; 122: 238-45.
10. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, Schiffman MH, Scott DR, Apple RJ. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000; 38: 357-61.
11. Kulmala SM, Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Podistov J, Ivanchenko O, Zakharenko S, Nerovjna R, Hjukina L, Branovskaja M, Grunberga V, Juschenko A, Tosi P, Santopietro R, Syrjanen K. Human papillomavirus testing with the hybrid capture 2 assay and PCR as screening tools. J Clin Microbiol 2004; 42: 2470-5.
12. Lörincz A, Anthony J. Advances in HPV detection by hybrid capture. Papillomavirus Rep 2001; 12: 145-54.
13. Peyton CL, Schiffman M, Lörincz AT, Hunt WC, Mielzynska I, Bratti C, Eaton S, Hildesheim A, Morera LA, Rodriguez AC, Herrero R, Sherman ME, Wheeler CM. Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol 1998; 36: 3248-54.
14. de Cremoux P, Coste J, Sastre-Garau X, Thioux M, Bouillac C, Labbe S, Carter I, Ziol M, Dosda A, Le Gales C, Molinie V, Vacher-Lavenu MC, Cochand-Priollet B, Vielh P, Magdelenat H, French Society of Clinical Cytology Study Group. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. Am J Clin Pathol 2003; 120: 492-9.
15. Federschneider JM, Yuan L, Brodsky J, Breslin G, Betensky RA, Crum CP. The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis. Am J Obstet Gynecol 2004; 191: 757-61.
16. Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high risk cocktail. J Clin Virol 2002; 25 (Suppl. 3): S89-S97.
17. Schneede P, Hillemanns P, Ziller F, Hofstetter A, Stockfleth E, Arndt R, Meyer T. Evaluation of HPV testing by Hybrid Capture II for routine gynecologic screening. Acta Obstet Gynecol Scand 2001; 80: 750-2.
18. Solomon D, Schiffman M, Tarone R, the ALTS Study Group. Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000; 92: 397-402.
19. Terry G, Ho L, Londesborough P, Cuzick J, Mielzynska-Lohnas I, Lörincz A. Detection of high-risk HPV types by the Hybrid Capture 2 test. J Med Virol 2001; 65: 155-62.
20. Yamazaki H, Sasagawa T, Basha W, Segawa T, Inoue M. Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. Int J Cancer 2001; 94: 222-7.
21. van Ham MA, Bakkers JM, Harbers GK, Quint WG, Massuger LF, Melchers WJ. Comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol 2005; 43: 2662-7.
22. Monsonego J, Bohbot JM, Pollini G, Krawec C, Vincent C, Merignargues I, Haroun F, Sednaoui P, Monfort L, Dachez R, Syrjanen K. Performance of the Roche AMPLICOR human papillomavirus (HPV) test in prediction of cervical intraepithelial neoplasia (CIN) in women with abnormal PAP smear. Gynecol Oncol 2005; 99: 160-8.
23. Tieben LM, ter Schegget J, Minnaar RP, Bouwes Bavinck JN, Berkhout RJ, Vermeer BJ, Jebbink MF, Smits HL. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods 1993; 42: 265-79.
24. Kocjan BJ, Poljak M, Seme K, Potočnik M, Fujs K, Babič DZ. Distribution of human papillomavirus genotypes in plucked eyebrow hairs from Slovenian males with genital warts. Infect Genet Evol 2005; 5: 255-9.
25. Greer CE, Peterson SL, Kiviat NB, Manos MM. PCR amplification from paraffin-embedded tissues: effects of fixative and fixation time. Am J Clin Pathol 1991; 95: 117-24.
26. Poljak M, Seme K, Gale N. Detection of human papillomaviruses in tissue specimens. Adv Anatomic Pathol 1998; 5: 216-34.
27. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, Delius H, Peyton CL, Bauer HM, Wheeler CM. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994; 170: 1077-85.
28. Perrons C, Jelley R, Kleter B, Quint W, Brink N. Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J Clin Virol 2005; 32: 278-85.
29. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201: 1-6.